Hamartia Antidote
ELITE MEMBER
- Joined
- Nov 17, 2013
- Messages
- 35,188
- Reaction score
- 30
- Country
- Location
https://www.afr.com/world/north-ame...report-coronavirus-drug-works-20200417-p54kov
Gilead Sciences shares climbed in late trading Thursday after a report that a group of patients being treated in Chicago were seeing "rapid recoveries" in coronavirus fever and respiratory symptoms.
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead's drug remdesivir.
The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died, according to Stat.
Gilead's drug is one of the most-watched therapies being studied for treatment of Covid-19 patients.
It's conducting two trials of the drug in moderate and severe patients, with the goal of enrolling 4,000 people in the trials.
The University of Chicago enrolled 125 patients, most of whom had severe disease, according to Stat.
Shares of the company surged 10 per cent in trading after the market closed.
The Chicago results are a tiny but promising sliver of the overall trial. Almost all patients recover from the disease, which has made it important to conduct tests which compare treatments against a placebo. While the trial in moderate patients contains a placebo group, Gilead's trial of severe patients does not.
Mullane didn't immediately respond to a request for comment. Researchers have collected information from the first 400 patients enrolled in the trial and Gilead plans to "lock" the data on Thursday, meaning the results could come soon, Stat said.
Wall Street futures have shot 3 per cent higher at the open this morning, as US President Donald Trump outlined the guidelines to allow the US economy to re-open.
Gilead Sciences shares climbed in late trading Thursday after a report that a group of patients being treated in Chicago were seeing "rapid recoveries" in coronavirus fever and respiratory symptoms.
The report, from the medical news publication Stat, cited a video made by a researcher at the University of Chicago who is helping conduct a trial of Gilead's drug remdesivir.
The researcher, infectious disease professor Kathleen Mullane, said that most patients had been discharged from the hospital and only two had died, according to Stat.
Gilead's drug is one of the most-watched therapies being studied for treatment of Covid-19 patients.
It's conducting two trials of the drug in moderate and severe patients, with the goal of enrolling 4,000 people in the trials.
The University of Chicago enrolled 125 patients, most of whom had severe disease, according to Stat.
Shares of the company surged 10 per cent in trading after the market closed.
The Chicago results are a tiny but promising sliver of the overall trial. Almost all patients recover from the disease, which has made it important to conduct tests which compare treatments against a placebo. While the trial in moderate patients contains a placebo group, Gilead's trial of severe patients does not.
Mullane didn't immediately respond to a request for comment. Researchers have collected information from the first 400 patients enrolled in the trial and Gilead plans to "lock" the data on Thursday, meaning the results could come soon, Stat said.
Wall Street futures have shot 3 per cent higher at the open this morning, as US President Donald Trump outlined the guidelines to allow the US economy to re-open.
